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Is Growing Up, But Kids Do
the Darndest Things*
Blase A. Carabello, MDI n this issue of JACC: Cardiovascular Interventions,Webb et al. (1) report the 2-year follow-up of theB arm of the PARTNER II (Placement of Aortic
Transcatheter Valves II) trial in which patients with
severe inoperable symptomatic aortic stenosis were
randomized to receive transcatheter aortic valve
replacement (TAVR) with the SAPIEN versus the
SAPIEN XT valve (Edwards Lifesciences, Irvine, Cali-
fornia). Both valves are balloon-expandable bovine
pericardial bioprostheses. The SAPIEN valve is deliv-
ered using a 22- or 24-F introducer sheath, whereas
the lower-proﬁle SAPIEN XT valve is delivered using
a smaller 18- or 19-F sheath. Both groups of patients
were required to have vascular access capable of
receiving either valve.SEE PAGE 1797FEWER VASCULAR COMPLICATIONS
Not surprisingly, the current trial found that the
lower-proﬁle SAPIEN XT produced substantially
fewer vascular complications and fewer major
vascular complications resulting in fewer blood
transfusions. Placing smaller devices inside arteries is
safer than implanting larger ones. That’s where the
expected results end. Remarkably, the lower-proﬁle
XT valve did not cause fewer early deaths or fewer
early strokes than the ﬁrst-generation SAPIEN. In the
past, vascular complications and the need for blood
transfusion have almost always translated into
increased morbidity and mortality (2–5). This result is*Editorials published in JACC: Cardiovascular Interventions reﬂect the
views of the authors and do not necessarily represent the views of JACC:
Cardiovascular Interventions or the American College of Cardiology.
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patients likely would destabilize with the pain and
blood loss associated with vascular injury. Although
indeed the fewer complications caused by the XT
implantation is a laudable and obviously a preferable
outcome, why didn’t fewer complications and more
facile implantation translate into fewer deaths and
fewer strokes? This later ﬁnding is even more sur-
prising because the current trial employed stricter
neurological surveillance than did the PARTNER I
trial. The answer probably lies in experience. The
operators in the PARTNER II trial were usually the
same as those from the PARTNER I trial, and though
complications occurred more frequently with the
early-generation valve, seasoned operators probably
dealt with them in a more expedient, effective
manner, leading to fewer deaths and strokes in the
second trial.
PARAVALVULAR LEAK
In the current study, the incidence of moderate or
severe paravalvular leak (PVL) was about 20%, almost
double that seen in the PARTNER I trial and not
different between the 2 arms of the trial even though
the SAPIEN valve used in 1 arm was identical between
the PARTNER I and II trials. The authors postulate
that the difference is one of different core lab grade
interpretation rather than an actual increase in the
rate of this complication. This seems logical because
reported mortality was similar between the 2 PART-
NER trials. Because post-TAVR aortic regurgitation is
accepted as a cause of increased mortality (6–8), yet
mortality was not different, the magnitude of PVL
was also probably not signiﬁcantly different between
the PARTNER I and II trials. Although the whole issue
of PVL may be rendered moot by ever-improving
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1808TAVR designs that reduce or prevent PVL, the
assessment of PVL is still relevant. Often missed in
this assessment of PVL is its impact on the left
ventricle (LV). This impact is based, not only on the
severity of the leak itself, but also on its interaction
with LV compliance. Thus, a relatively smaller leak
could have more impact on a very stiff LV than a
greater leak on a more compliant LV (9), so that PVL
severity by itself is probably not an adequate deter-
minant of outcome.
MATURING OF TAVR:
PARTNER I VERSUS PARTNER II
Thus, the lower-proﬁle SAPIEN XT TAVR led to fewer
vascular complications, fewer major vascular com-
plications, and less bleeding than did the bulkier
ﬁrst-generation SAPIEN valve (1). This outcome was
predictable (did we need a trial to prove it?); indeed,
it would have been very surprising if the next-
generation valve had had no beneﬁt. However, we
have learned more than that from this trial. Two-year
mortality was similar and substantial (about 35%)
between both arms of this trial, also similar to the
PARTNER I trial. This high rate almost surely stems
from the very ill nature of these inoperable patients.
In order to reach an STS score of 10 to 12 (found in the
2 trials), patients must have signiﬁcant extracardiac
comorbidities, conditions not treated by TAVR. Thus,
improvement in the valve did not improve mortality.
However, an apparent reduction in stroke rate be-
tween the PARTNER I and II trials and likely more
effective treatment of vascular complications when
they occur indicate improved operator judgment andskill as the procedure has matured—and this is only
the beginning. Further reﬁnement in valve design,
patient selection, and operator skill will make TAVR
progressively safer to employ, and as procedures
become safer, they become more applicable. What
will the TAVR of a decade from now be like? New
designs are already reducing PVL (10). Valve proﬁle
will progressively decrease toward some theoretical
minimum. Although surely structural deterioration
will be a concern as it is with all biological valves,
especially as they are applied to younger patients, it is
interesting that TAVR in older patients has shown
very little sign of this complication. Could it be that
the inherent differences in TAVR design compared
with other bioprostheses somehow conveys better
durability? Finally, carotid protection devices in
concert with easier delivery will likely further
decrease stroke risk.
These advances will challenge us in our manage-
ment decisions. Will each new advance require a
clinical trial for vetting? How will new designs affect
our decisions about treatment with surgical valve
replacement? How will patient preference affect our
decisions even when their preference goes counter to
existing data? It will be a great, but gratifying, chal-
lenge to help TAVR grow up to be an adult member of
our therapeutic armamentarium. Hang on to your
hats, it will be quite a ride!
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